HCSG and IMPLICITY® Offer German Cardiologists a Complete Solution for Remote Monitoring The two companies offer a complete solution for German telemedicine centers, including equipping patients with the devices and a TMZ portal for heart failure remote monitoring with external sensors and implants. Munich and Paris, May 20th, 2022 — HCSG and IMPLICITY, two leading providers of remote monitoring solutions in the field of cardiology, announced today the conclusion of a cooperation agreement. The two companies’ offer is aimed at German cardiologists who want to operate their own telemedicine center (TMZ). Remote monitoring of patients with cardiac insufficiency (heart failure) has recently become part of the outpatient services offered by the statutory health insurance funds. Remote monitoring can be prescribed topatients with heart failure if they have been hospitalized in the last 12 months or are wearing a suitable implant. To implement remote monitoring, a TMZ must use either external devices (scales, ECG, blood pressure monitors and patient app) or implants (dedicated pacemakers and defibrillators). HCSG specializes in remote monitoring with external devices, while IMPLICITY processes implant data from all major manufacturers for cardiologists. With the complete solution from HCSG and IMPLICITY, consisting of devices, software, service and consulting, cardiologists can immediately set up their own TMZ. The system has already proven itself in practice: « In our TMZ, we use both implants and external sensors for remote monitoring. All data is clearly displayed in a TMZ portal. This enables limit value analyses with the least possible effort, » says Dr. Ali Halboos from the GiG Telemedicine Center, Germany. The Gesellschaft für integrierte Gesundheitsversorgung (GiG) operates 17 cardiological practices whose locations are mainly in NRW and southern Germany. « Seeing the most important information from all manufacturers automatically and at a glance allows me to provide my patients with very efficient and optimal care in remote monitoring. The user-friendly implementation of the cloud-based platform is a concrete example of IMPLICITY’s many years of experience. One example: the automatic notification of patients for whom transmissions have failed makes our day-to-day work much easier », says Dr. Lutz Sinn from the practice for cardiovascular medicine in Bad Säckingen, Germany. « I don’t want to worry about the issue of equipment, and I don’t want to have anything to do with it if there is a malfunction of the equipment or a problem with the data transmission. But I just want to know exactly when the patient is getting worse. That’s where we benefit from HCSG, which has already provided such services », says Prof. Dr. Martin Bergmann from the Cardiologicum Hamburg. With over 60,000 treatment cases per year, the Cardiologicum Hamburg is one of the largest outpatient care centers for cardiovascular medicine in Germany. ————————— About IMPLICITY® IMPLICITY is a digital medical technology company that provides healthcare providers with a universal remote monitoring platform that aggregates data from implantable cardiac implants from all major manufacturers and presents it in a uniform manner. IMPLICITY is also developing AI and knowledge-based algorithms to reduce the burden on physicians and enable them to predict the health status of patients. IMPLICITY serves more than 60,000 patients in 100 medical facilities in Europe and the US. Contact: Karsten HagemannTel: +33 680 105065 | Email: karsten.hagemann@implicity.com   About HCSG Health Care Systems GmbH is a leading provider of digital precision medicine solutions. The HCSG team has more than 15 years of experience in providing telemedical care to over 70,000 patients with heart failure. Today, HCSG serves patients throughout Germany and Switzerland with over 60 employees at three locations. HCSG has developed the hedy Telemonitoring Program specifically for use in telemedicine centers. Contact:Dr. med. Christian KlossTel: 089 444 889 102 | Email: info@hcsg.de

IMPLICITY Raises $23M to Broaden Use of Its Cardiac Remote Monitoring Platform Series A funding round will accelerate international expansion and fuel AI-based medical algorithm development. Cambridge, Mass., April 27th, 2022 – IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today announced it has raised $23 million in Series A funding led by new investors: Crédit Mutuel Innovation and Bpifrance. Additional investors for the round include BNP Paribas Development and previous seed investors: Serena, XAnge and Karista. This new funding comes just months after IMPLICITY received FDA clearance for a novel AI algorithm that analyzes ECG episodes from Implantable Loop Recorders (ILRs). “This financing round marks a new and exciting chapter for IMPLICITY. With clinical staff everywhere wrestling with an increasing volume of data coming from the growing number of connected devices, the need for a universal remote platform is now widely recognized as paramount. Coverage of remote care sparked by Covid-19 set the scene. In order to democratize remote cardiac care, our mission is to provide healthcare professionals with the best technology available to scale and monitor all cardiac patients,” said Dr. Arnaud Rosier, CEO and founder of IMPLICITY. The new funding will help speed the international rollout of IMPLICITY’s AI-based technology and cardiac data management solutions — enabling healthcare professionals around the world with a more holistic approach to caring for cardiac patients. Proceeds will be used to: Increase the company’s market presence in the US and support expansion into new markets Develop additional medical device software to strengthen the technological leadership of the company “We are very pleased to support the commercial expansion of IMPLICITY’s cutting-edge platform that enables cardiologists to provide more effective patient care by streamlining data across major remote cardiac monitoring devices,” said Delphine Cardi, Investment Director at Crédit Mutuel Innovation. “The company is already on a strong growth path in the U.S. and Europe, and we look forward to building on that momentum as they continue to develop next-generation offerings that move toward the prevention of heart disease.” “We are extremely impressed by IMPLICITY’s current international market success. We believe the company has the potential to become a world-class leader in cardiac remote monitoring. This investment will help accelerate adoption across all regions in 2022 and beyond, particularly in the U.S. This is a very large market opportunity that cannot be overstated,” said Chahra Louafi, Director of the Autonomous Patient Fund at Bpifrance. About IMPLICITY®IMPLICITY® is a software company that provides a universal cardiac remote monitoring and research platform to clinics and service companies, helping them provide the best remote care to cardiac patients. As a digital Medtech, IMPLICITY® develops AI and knowledge based algorithms to reduce healthcare professionals’ workload and allows them to potentially predict patient health status. The IMPLICITY® platform aggregates, normalizes and standardizes data from all implantable cardiac electronic device across all major manufacturers. In addition to having an FDA cleared solution and multiple CE markings, IMPLICITY® has been the first private company authorized to access the Health Data Hub*, one of the world’s largest patient databases     , supporting the development of its AI solutions to improve care for patients with chronic heart failure conditions. IMPLICITY® covers more than 60,000 patients in 100 medical facilities across the United States and Europe. * Health Data Hub is a health data platform put in place by the French government to combine existing health patient databases and facilitate their usage for research and development purposes. About Crédit Mutuel Innovation Crédit Mutuel Innovation is the venture capital subsidiary of Crédit Mutuel Equity (€3.5 billion of capital under management), part of Crédit Mutuel Alliance Fédérale. It invests tickets between €1m and €20m in innovative companies in the digital, life sciences and deeptech sectors. Crédit Mutuel Innovation enables entrepreneurs to develop their growth potential by connecting them to companies in the ecosystems it belongs. Because it takes more than five years to create a world leader, Crédit Mutuel Innovation invests (and often reinvests) its own capital on a long-term basis and builds long-term relationships with the entrepreneurs it supports. About Bpifrance and FPA Bpifrance‘s equity investments are made by Bpifrance Investissement. Bpifrance finances companies—at each stage of their development—​​with loans, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance now also ensures their export activity through a wide range of products. Advice, university, networking and acceleration programs for startups, SMEs and ETIs are also part of the offer offered to entrepreneurs. Thanks to Bpifrance and its 50 regional locations, entrepreneurs benefit from a close, unique and efficient interlocutor to support them in facing their challenges. Bpifrance’s Autonomous Patient Fund, launched in early 2018, targets startups which develop innovations that allow: Optimization of health costs—Better care by helping to strengthen the relationship between a health professional and his patient (telemedicine, remote monitoring, digital therapies), An improvement in the quality and efficiency of care, Improvements in the care pathway, in particular for chronic diseases (diabetes, cancers, mental health, etc.), by helping to prevent diseases and their complications, by facilitating the diagnosis of the disease and by monitoring its evolution over time real, in particular thanks to artificial intelligence, « deep/machine learning.”

Cardiac Remote Monitoring Research: A Clear Opportunity for Transforming Patient Care Cardiac health issues typically require frequent monitoring, regular interventions, and quick decision-making when symptoms arise, which can place significant burdens on patients.  Accessing the most appropriate care for the situation can be a major challenge for these individuals, especially those facing transportation issues, family and work obligations, or other financial stressors that influence their care choices. Fortunately, new technologies are making it much easier for cardiac patients and their providers to make timely, informed decisions and when, how, and where to seek care. Cardiac remote monitoring (CRM) tools, including connected implantable devices, external monitors, and smartphone apps, can empower patients and caregivers to monitor ongoing health, identify emerging risks, and address issues before they turn into bigger problems. With nearly half of all U.S. adults at risk of developing some form of heart disease and an estimated 6-12 million people worldwide suffering with atrial fibrillation (a common heart arrhythmia that can lead to blood clots in the heart and increase the risk of stroke and heart failure), there is a clear and pressing need to deploy robust, patient-friendly CRM tools on a much broader scale. To do so, the healthcare community must continue to engage in innovative research and develop a better understanding of how these technologies impact patient self-care, utilization of resources, and long-term health outcomes. Harnessing the growing interest in Cardiac Remote Monitoring Even before the COVID-19 pandemic, remote patient monitoring (RPM) was a hot topic for healthcare providers searching for more efficient, less intrusive ways to stay connected with patients.  Using a combination of internet-enabled devices, smartphone apps, and audio or video chats, providers were already staying connected with more than 29 million patients at the start of the pandemic. The public health crisis has only intensified interest in tech-enabled care at home.  In addition to successfully using RPM strategies to avoid hospitalizations from the virus, providers and patients are both eager to use remote care for chronic disease management without the need to meet face-to-face. As of April 2021, close to a quarter of practices surveyed by the Medical Group Management Association (MGMA) stated that they were already offering RPM to their patients.  This tracks with predictions that the remote care market will be worth a staggering $1.7 billion by 2027, representing a 128 percent increase from current levels. Building the case for wider use of remote monitoring technologies Cardiac remote monitoring is likely to represent a major segment of that dynamic marketplace.  With such strong interest and so many individuals potentially eligible for cardiac monitoring, it’s no wonder that researchers have been actively exploring the impact of CRM on patient experiences, healthcare spending, and clinical outcomes. Many recent studies agree that CRM is a safe and viable alternative to traditional care strategies, highlighting the potential for CRM to actively reduce costs, avoid hospitalizations, and engage patients in their own care. For example, the landmark ECOST study found that remote monitoring of individuals with implantable cardioverter defibrillators (ICDs) resulted in fewer major adverse events than the standard of care.  Remote monitoring also helped reduce the number of shocks delivered, including a 52 percent reduction in inappropriate shocks.  Not only did patients have a better experience with remote monitoring, but the batteries in their devices lasted longer due to less usage. Moreover, the study proved that remote monitoring decreased costs for payers. A separate study also found improved patient adherence to care with CRM. Individuals participating in remote monitoring were notably more likely to stay adherent to regular checks and scheduled follow-ups compared to people undergoing conventional care. Lastly, CRM can help to control health system spending by reducing avoidable utilization.  In a recent European multi-center trial, researchers found a 79 percent reduction in planned in office evaluations – and no increase in unplanned clinic visits – among patients who only used home monitoring to manage their conditions.  Providers also saved time with these patients. CRM slashed the length of follow-up visits in half for remote-only patients. These and other ongoing studies show that CRM is a promising way to safely and effectively improve patient experiences, but aslo avoid unnecessary costs without negatively impacting clinical outcomes. Translating knowledge into action with an innovative CRM platform As a clinician-founded and outcomes-driven member of the CRM community, Implicity is excited to see the evidence building in favor of remote care for cardiac patients.  We strongly believe that data-driven remote care is transformative for patients and their clinicians, offering the chance to get ahead of developing concerns and promoting the delivery of preventive actions. Because we are so passionate about showcasing the power of remote care for cardiac conditions, we want to do our part to support innovation and evidence-based medicine.  That’s why we are launching our first Cardiac Remote Monitoring Contest to accelerate research into this critical topic. We are offering our platform to researchers who need to collect, analyze, and report on the raw data gathered from cardiac implants. Our tools can help examine outcome data, investigate processes, analyze economic impacts, gather insight on patient experiences, and more. As interest in remote cardiac monitoring continues to increase, this is a pivotal moment for technology developers, researchers, and clinicians.  We must work together to generate successful, high-quality research that can inform proactive, effective decision-making for clinicians, healthcare executives, and patients. To meet our independent panel of judges and to apply for the contest, please click here. Arnaud Rosier, CEO of IMPLICITY®.

IMPLICITY® to Showcase New Artificial Intelligence-based Innovations in Remote Cardiac Monitoring at HRS 2022 A key highlight will include a Rhythm Theater presentation focused on the constraints and challenges of remote cardiac monitoring (RCM), as well as the impact of AI in managing ILR dataflows and transforming RCM into an opportunity for clinical research. Cambridge, Mass., April 19th, 2022  – IMPLICITY®, a global leader in remote patient monitoring and cardiac data management solutions, is showcasing its portfolio of remote cardiac monitoring solutions at the upcoming Heart Rhythm 2022 (HRS 2022) in San Francisco, California, hosted by the Heart Rhythm Society, between April 29th and May 1st, 2022.  A key highlight will be a Rhythm Theater presentation titled, “Management of CIEDs with New Remote Monitoring Features: From Standard of Care to Artificial Intelligence,” on Friday, April 29, 2022, at 2:15 pm PST in the Innovation Expo, Booth 2155.  “Using CIEDs for remote monitoring (RM) is now considered the standard of care, but they add a significant burden for clinicians because they have a high false-positive rate. Our panel session will explore how novel technologies such as AI can significantly reduce this workload and help streamline clinic workflows,” said Dr. Arnaud Rosier, Ph.D., electrophysiologist, and CEO and co-founder of IMPLICITY®. Key opinion leaders on the panel include:  Niraj Varma, MB, ChB, FACC, Professor of Medicine and Consultant Electrophysiologist at the Cleveland Clinic, who pioneered the use of remote monitoring technology for implantable devices. Varma will chair the session and discuss how artificial intelligence (AI) is transforming the management of implantable loop recorder (ILR) data. Suneet Mittal, MD, FACC, FHRS, Director of the Electrophysiology Laboratory, and Associate Chief of Cardiology at The Valley Hospital in Ridgewood, New Jersey. He will share insights on remote monitoring as a standard of care, exploring various constraints and challenges.  As part of the session, Dr. Rosier will also explain how remote patient monitoring (RPM) can support opportunities for clinical research. IMPLICITY® recently launched a unique competition offering investigators a chance to gain free access to IMPLICITY®’s platform to support their studies with support from IMPLICITY®’s team of data scientists and engineers.  IMPLICITY® announced FDA clearance for its AI-powered ILR ECG Analyzer for Implantable Loop Recorders in December 2021. The company’s full suite of innovative solutions will be on display at the HRS 2022 event at booth #1641.  About IMPLICITY®IMPLICITY® is a digital MedTech that provides a universal remote cardiac monitoring and research platform to medical centers and service companies, helping them provide the best remote care to cardiac patients. IMPLICITY® develops AI and knowledge based algorithms to reduce healthcare professionals workload and allow to potentially predict patient health status. The IMPLICITY® platform aggregates, normalizes and standardizes data from all implantable cardiac electronic device across all major manufacturers. In addition to having an FDA cleared solution and multiple CE markings, IMPLICITY® has been the first private company authorized to access the Health Data Hub*, one of the world largest patient database, supporting the development of its AI solutions to improve care for patients with chronic heart failure condition. IMPLICITY® covers more than 60,000 patients in 100 medical facilities across the United States and Europe. For more information, visit: https://implicity.com   * Health Data Hub is a health data platform put in place by the French government to combine existing health patient databases and facilitate their usage for research and development purposes